6/26/2025

NEW HYDE PARK, N.Y., June 26, 2025--For the first time, TIME has named Northwell Health, the largest health system in the Northeast, to its TIME100 Most Influential Companies 2025 list. Northwell is the only health system to be recognized on the prestigious list which highlights companies making a difference in 2025, acknowledging innovation, ambition and success. TIME aims to showcase diverse forms of influence and offer examples of impactful corporate leadership. Other companies on the list in

Source: Yahoo

6/26/2025

Stifel analyst Alex Thompson is reiterating a Buy rating on Kymera Therapeutics (KYMR) following “a slate of updates,” including the decision by partner Sanofi (SNY) to discontinue development of lead IRAK4 degrader KT-474 in favor of next-gen KT-485 and a new partnership deal with Gilead (GILD) for a CDK2 molecular glue degrader. While the update related to IRAK4 is “disappointing and removes potential catalysts” next year, Sanofi expects to move KT-485 into Phase 1 next year and the broader pa

Source: Yahoo

6/26/2025

Futures are flat to slightly higher as the Israel‑Iran ceasefire remains stable and investor focus shifts to another day of testimony from Fed Chair Powell. Oil prices have steadied around $65-$66 per barrel after a recent drop, easing inflation pressures and supporting equities. Treasury yields and the dollar have softened, buoyed by speculation that the Fed may cut rates as soon as July or September. Equities closed near record highs yesterday as tech remains in favor, led by chipmakers such a

Source: Yahoo

6/26/2025

Kymera's shares drop as Sanofi ends KT-474 development, but Gilead's oncology deal remains positive.

Source: Yahoo

6/26/2025

Date of Publication:30/6/2025 Full Name ...

Source: Finnhub

6/25/2025

Gilead Sciences (GILD) concluded the recent trading session at $105.93, signifying a -1.18% move from its prior day's close.

Source: Yahoo

6/25/2025

Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, June 27, 2025, the Index will be rebalanced, and the following changes will be effective.

Source: Yahoo

6/25/2025

Gilead Sciences (NasdaqGS:GILD) recently entered an exclusive agreement with Kymera Therapeutics to advance a molecular glue degrader program targeting CDK2, enhancing its oncology pipeline. Additionally, the FDA approved Yeztugo as a breakthrough HIV prevention option. Both events underscore Gilead's strength in innovation. Despite these developments, Gilead's share price remained flat over the past month, contrasting with the broader market's 1.9% rise in seven days. While these initiatives...

Source: Yahoo

6/25/2025

Yetzugo is a long-acting HIV-1 capsid inhibitor that reduces the risk of sexually acquired HIV in adults and adolescents.

Source: Yahoo

6/25/2025

Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors

Source: MarketWatch

6/25/2025

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers hope. Click for my GILD and KYMR update.

Source: SeekingAlpha

6/25/2025

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a new drug prospect, meanwhile.

Source: Yahoo

6/25/2025

– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean plasma HBV DNA reductions of 3.2 logs IU/mL over 28 days of treatment for 400 mg cohort consistent with findings in 150 mg cohort, supporting ability of 150 mg dose to achieve saturated inhibition of viral replication, as anticipated – – Trial completion triggers opt-in point under collaboration with Gilead Sciences, Inc. following d

Source: Yahoo

6/25/2025

FOSTER CITY, Calif. & WATERTOWN, Mass., June 25, 2025--Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential including in breast cancer and other solid tumors.

Source: Yahoo

6/25/2025

Gilead Sciences has enteredinto an option and license deal with Kymera Therapeuticsto support the development and sales of a class ofcancer drugs, the companies said on Wednesday. As...

Source: Finnhub

6/25/2025

Explore May 2025 market volatility, U.S.-China trade talks, and record dividend income growth.

Source: SeekingAlpha

6/25/2025

The AMG Boston Common Global Impact Fund returned -3.81% for the first quarter of 2025, compared with -1.33% for the benchmark, the MSCI ACWI Index.

Source: SeekingAlpha

6/25/2025

By Colin Kellaher Gilead Sciences and Kymera Therapeutics have inked an exclusive cancer-drug option and licensing agreement potentially worth hundreds of million of dollars to Kymera. The...

Source: Finnhub

6/24/2025

NORTHAMPTON, MA / ACCESS Newswire / June 24, 2025 / Kim Canady was only nine years old in 1996 when she faced the unimaginable loss of losing both her parents in the same year. At the time, she didn't know her parents suffered HIV-related complications, ...

Source: Yahoo

6/24/2025

‌Date of Publication: 30 June 2025 Full Name ...

Source: Finnhub